Literature DB >> 15972453

Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes.

Akira Matsuda1, Ulrich Germing, Itsuro Jinnai, Motohiro Misumi, Andrea Kuendgen, Sabine Knipp, Manuel Aivado, Masako Iwanaga, Yasushi Miyazaki, Hideki Tsushima, Mari Sakai, Masami Bessho, Masao Tomonaga.   

Abstract

Several reports indicate that there might be differences in clinical features between Asian and Western myelodysplastic syndrome (MDS) cases. We analyzed refractory anemia (RA) in French-American-British (FAB) classification cases diagnosed in Japan and Germany to perform a more exact comparison between Asian and Western MDS types. In the first step, we analyzed agreement of morphologic diagnosis between Japanese and German hematologists. Blood and bone marrow slides of 129 patients diagnosed with FAB-RA, FAB-RA with ringed sideroblasts (RARS), or aplastic anemia were selected randomly and evaluated separately by each group. The agreements of diagnoses according to FAB and World Health Organization (WHO) classifications were 98.4% and 83.8%, respectively. Second, we compared clinical features between 131 Japanese and 597 German patients with FAB-RA. Japanese patients were significantly younger than German patients. Japanese patients had more severe cytopenias. However, prognosis of Japanese patients was significantly more favorable than that of German patients. Japanese patients had a significantly lower cumulative risk of acute leukemia evolution than did German patients. Frequency of WHO-RA in Japanese patients with FAB-RA was significantly higher than that in German patients. In conclusion, our results indicate that the clinical features of Japanese patients with FAB-RA differ from those of German patients.

Entities:  

Mesh:

Year:  2005        PMID: 15972453     DOI: 10.1182/blood-2005-01-0040

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Prospective analysis of clinical and cytogenetic features of 435 cases of MDS diagnosed using the WHO (2001) classification: a prognostic scoring system for predicting survival in RCMD.

Authors:  Xiao Qin Wang; John Ryder; Sherilyn A Gross; Guowei Lin; Richard D Irons
Journal:  Int J Hematol       Date:  2009-08-29       Impact factor: 2.490

2.  Features of Japanese patients with myelodysplastic syndrome in an aging population of Sado Island.

Authors:  Kumiko Yagisawa; Kiyoshi Okazuka; Ken Toba; Masaru Urushiyama; Takashi Kuroha; Noriko Izumi; Yasuhiko Sibasaki; Masutaka Higashimura; Toshio Yano; Akihito Momoi; Akira Hattori; Ken Momotsu; Yoshifusa Aizawa
Journal:  Int J Hematol       Date:  2012-02-24       Impact factor: 2.490

3.  Aurora-B expression may not contribute to disease progression: a reflection of the heterogeneous pathogenesis?

Authors:  Fabiola Fernandes Heredia; Juliana Cordeiro de Sousa; Alex Fiorini Carvalho; Silvia Maria Meira Magalhaes; Ronald Feitosa Pinheiro
Journal:  Haematologica       Date:  2012-10       Impact factor: 9.941

4.  A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome.

Authors:  Je-Hwan Lee; Jun Ho Jang; Jinny Park; Seonyang Park; Young-Don Joo; Yeo-Kyeoung Kim; Hoon-Gu Kim; Chul Won Choi; Sung-Hyun Kim; Seong Kyu Park; Eunkyung Park; Yoo Hong Min
Journal:  Haematologica       Date:  2011-06-09       Impact factor: 9.941

5.  A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-)CD59(-) blood cells predicts platelet response.

Authors:  Takayuki Ishikawa; Kaoru Tohyama; Shinji Nakao; Yataro Yoshida; Masanao Teramura; Toshiko Motoji; Masaaki Takatoku; Mineo Kurokawa; Kinuko Mitani; Takashi Uchiyama; Mitsuhiro Omine
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

6.  A nationwide non-interventional epidemiological data registry on myelodysplastic syndromes in Lebanon.

Authors:  Zaher K Otrock; Nabil Chamseddine; Ziad M Salem; Tarek Wehbe; Mouna Al-Ayoubi; Moussa Dhaini; Joseph Kattan; Walid Mokaddem; Therese Abi Nasr; Oussama Jradi; Fadi S Farhat; Mahmoud Wehbe; Mohammad H Haidar; Mohamed A Kharfan-Dabaja; Nizar Bitar; Mirna El Hajj; Adel M Kadri; Francois G Kamar; Hanan Yassine; Hassan Khodr; Ali T Taher; Noha Hakime; Rami Ar Mahfouz; Wassim Serhal; Ali Bazarbachi; Hussein Z Farhat
Journal:  Am J Blood Res       Date:  2015-12-25

7.  Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study.

Authors:  Kiyoyuki Ogata; Matteo G Della Porta; Luca Malcovati; Cristina Picone; Norio Yokose; Akira Matsuda; Taishi Yamashita; Hideto Tamura; Junichi Tsukada; Kazuo Dan
Journal:  Haematologica       Date:  2009-06-22       Impact factor: 9.941

8.  Diagnosed hematological malignancies in Bangladesh - a retrospective analysis of over 5000 cases from 10 specialized hospitals.

Authors:  Mohammad Sorowar Hossain; Mohd S Iqbal; Mohiuddin Ahmed Khan; Mohammad Golam Rabbani; Hazera Khatun; Sirajam Munira; M Morshed Zaman Miah; Amin Lutful Kabir; Naima Islam; Tashmim Farhana Dipta; Farzana Rahman; Abdul Mottalib; Salma Afrose; Tasneem Ara; Akhil Ranjan Biswas; Mizanur Rahman; Akm Mustafa Abedin; Mahbubur Rahman; A B M Yunus; Louis W Niessen; Tanvira Afroze Sultana
Journal:  BMC Cancer       Date:  2014-06-14       Impact factor: 4.430

9.  Distinct clinical and experimental characteristics in the patients younger than 60 years old with myelodysplastic syndromes.

Authors:  Xiao Li; Zhi-jian Xiao; Chun-kang Chang; Feng Xu; Ling-yun Wu; Qi He; Ze-feng Xu; Lu-xi Song; Zheng Zhang; Li-yu Zhou; Ji-ying Su; Xi Zhang; Juan Guo
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

Review 10.  Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.

Authors:  Norbert Gattermann
Journal:  Int J Hematol       Date:  2008-06-27       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.